Verastem Set to Rise on Promising Cancer Drug Pipeline
AI Prediction of Verastem, Inc. (VSTM)
Verastem Inc., a biopharmaceutical company, is poised for growth with its FDA-approved drug for KRAS-mutant low-grade serous ovarian cancer (LGSOC) and other promising candidates targeting RAS/MAPK pathway-driven cancers.
Verastem Inc. focuses on developing treatments for cancers driven by the RAS/MAPK signaling pathway. Its flagship product, AVMAPKI FAKZYNJA CO-PACK, recently received FDA approval for KRAS-mutant recurrent LGSOC, marking a significant milestone. The company's pipeline includes VS-7375, a KRAS G12D inhibitor, currently in early-stage trials. Upcoming catalysts, such as further clinical results and potential new drug approvals, could significantly impact the company's stock price in the near term. The recent FDA approval and promising pipeline position Verastem to capitalize on the growing demand for targeted cancer therapies.
VSTM Report Information
Prediction Date2026-03-06
Close @ Prediction$6.15
Mkt Cap492m
IPO Date2012-01-27
AI-derived Information
Recent News for VSTM
- Mar 5, 12:03 am — Verastem Inc (VSTM) Q4 2025 Earnings Call Highlights: Transition to Commercial Stage and ... (GuruFocus.com)
- Mar 4, 8:48 pm — Verastem Q4 Earnings Call Highlights (MarketBeat)
- Mar 4, 5:10 pm — Verastem (VSTM) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
- Mar 4, 4:20 pm — Verastem: Q4 Earnings Snapshot (Associated Press Finance)
- Mar 4, 4:01 pm — Verastem Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Business Updates (Business Wire)
- Feb 18, 7:30 am — Verastem Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026 (Business Wire)
- Feb 17, 12:00 pm — What Makes Verastem (VSTM) a New Buy Stock (Zacks)
- Feb 16, 1:02 am — Verastem Touts 50%+ Sales Growth for LGSOC Launch, Teases RAMP 301 and KRAS G12D Catalysts (MarketBeat)
- Feb 5, 11:42 am — Verastem Stock Rises Nearly 8% on Strong Q4 & 2025 Preliminary Results (Zacks)
- Feb 4, 8:00 am — Here Are Wednesdays Top Wall Street Analyst Research Calls: AES Corp, Airbnb, Cloudflare, Devon Energy, Levi Strauss, Lumentum, PayPal, and More (24/7 Wall St.)
- Feb 4, 7:30 am — Verastem Oncology Provides Preliminary Fourth Quarter and 2025 Revenue and Business Updates and Outlines 2026 Strategic Priorities for Novel Portfolio Targeting RAS/MAPK Pathway-Driven Cancers (Business Wire)
- Jan 30, 10:19 am — $668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors (PR Newswire)
NDAPR events for VSTM
No NDAPR events found.
Welcome to ScanScor. What you're reading is no ordinary summary -- it's the result of a carefully-crafted interactive session with OpenAI's most advanced models crafted from news, trial details, and financial data. This report attempts to maximize the potential for OpenAI's smartest GPT-based analysis engine, guided by tightly structured prompts to expose the forces behind today's market movers and to predict the future.
Disclaimer: This report is for informational purposes only. It does not constitute financial advice. Always do your own research before making any investment.
Subscribe
Login
Please login to comment
0 Comments
Oldest